On 21 May 2015, orphan designation (EU/3/15/1497) was granted by the European Commission to Prana Biotechnology UK Limited, United Kingdom, for 5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride for the treatment of Huntington's disease.
The sponsorship was transferred to Drug Development and Regulation S.L., Spain, in April 2019.
|Disease / condition||
Treatment of Huntington’s disease
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;